Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | FSCN1 | Q16658 | 1/20 | 0.40 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.35 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.35 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | APEX1 | P27695 | 1/20 | 0.32 |
| ▸ | UCHL1 | P09936 | 1/20 | 0.31 |
| ▸ | UCHL3 | P15374 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.30 |
| ▸ | MAP2K1 | Q02750 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9814181 | 0.79 | HSD17B10 (0.45) | GAAFSCN1ALDH1A1APEX1 | |
| SCHEMBL11506289 | 0.78 | FSCN1 (0.48) | GAAFSCN1ALDH1A1APEX1TSHR | |
| SCHEMBL16900683 | 0.74 | IDO1 (0.33) | SLC6A2SLC6A4SLC6A3ALDH1A1TSHR | |
| SCHEMBL21921083 | 0.71 | ALDH1A1 (0.41) | ALDH1A1UCHL1UCHL3 | |
| SCHEMBL31305311 | 0.69 | FSCN1 (0.70) | GAAFSCN1ALDH1A1TSHR | |
| SCHEMBL7127279 | 0.67 | MAP2K1 (0.41) | ALDH1A1TSHRMAP2K1 | |
| SCHEMBL4801242 | 0.67 | ALDH1A1 (0.58) | ALDH1A1HTT | |
| SCHEMBL22619017 | 0.67 | KDM4E (0.43) | GAAALDH1A1TSHRHTT | |
| SCHEMBL11504859 | 0.66 | FSCN1 (0.46) | GAAFSCN1SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL305505 | 0.64 | ALDH1A1 (0.63) | ALDH1A1TSHRMAP2K1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7381728-B2 | Piperazine derivatives useful for the treatment of gastrointestinal disorders | GLAXO GROUP LIMITED (GB) | 2008-06-03 | — | — | US | disclosed |
| US-20070259877-A1 | Piperazine Derivatives Useful for the Treatment of Gastrointestinal Disorders | GLAXO GROUP LIMITED | 2007-11-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070259877-A1 | Piperazine Derivatives Useful for the Treatment of Gastrointestinal Disorders | GHSR, GHRHR, GIPR | GAA 1116/4885FSCN1 4525/4885SLC6A2 2309/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.